Trial Title:
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
NCT ID:
NCT06315010
Condition:
NSCLC
Brain Metastases
ROS1 Gene Rearrangement
Conditions: Official terms:
Neoplasm Metastasis
Brain Neoplasms
Conditions: Keywords:
Metastatic NSCLC
Brain metastasis
ROS1
Repotrectinib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Repotrectinib
Description:
Repotrectinib is administered orally in capsule form, with each capsule containing size 0
hard gelatin 40 mg of the active compound in bottles containing 30 capsules.
Repotrectinib is administered orally in the form of capsules. The capsules are taken by
mouth and swallowed intact (without chewing, crushing, or opening) with water or another
suitable liquid.
Arm group label:
Repotrectinib
Other name:
BMS-986472
Other name:
TPX-0005
Summary:
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in
patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain
metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine
kinase (ROS1) gene.
Detailed description:
REPOSE is an international multicenter, open-label, single arm phase II clinical trial
designed to evaluate the efficacy of repotrectinib in patients with ROS1-positive NSCLC
with BM.
Upon meeting all selection criteria, a total of 20 participants confirmed ROS1
rearrangement will be enrolled. Participants who have received prior chemotherapy,
immunotherapy or other non-ROS1 tyrosine kinase inhibitor (TKI) are eligible.
Patients will continue study treatment until end of treatment (EoT) defined as the date
of disease progression, death, or discontinuation from the study treatment for any other
reason. After study treatment discontinuation, all participants will undergo a safety
visit (at 28 ± 7 days after last treatment dose) in order to follow up toxicities and
changes in concomitant medication. Patients discontinuing the study treatment at any time
will enter a post-treatment follow-up period during which survival and subsequent
anticancer therapy information will be collected every 3 months (± 7 days) from the
safety visit until death, lost to follow-up, elective withdrawal from the study, or the
end of study (EoS), whichever occurs first. Patients who discontinue treatment without
evidence of disease progression will be also followed for tumor assessments until
documented progression, elective withdrawal from the study, the start of new anti-cancer
treatment, or the EoS.
EoS is estimated to occur approximately 13 months after the last patient included in the
study initiates repotrectinib treatment, unless consent withdrawal, patient is lost to
follow-up, death, or premature termination of the study. EoS is defined as the last data
collection point at the last participant's safety visit and will occur after the study
treatment termination of the last patient in the study.
The main objective of REPOSE study is to determine the efficacy of repotrectinib at any
timepoint during the study period as determined locally by best central nervous system
(CNS) response, that is in terms of intracranial objective response rate (IC-ORR).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Patients will be included in the study only if they meet all the following criteria:
1. Patient must be capable to understand the purpose of the study and have signed
written informed consent form (ICF) prior to beginning specific protocol procedures.
2. Female or male patients ≥ 18 years of age at the time of signing ICF.
3. Patients must be capable to swallow capsules intact (without chewing, crushing, or
opening).
4. Histologically documented NSCLC.
5. Patients may have symptoms attributed to brain metastases.
6. No indication for immediate local therapy (neurosurgery, brain radiotherapy) of
brain metastases per local investigator.
Note: in case of immediate local therapy is needed, the study's medical monitor
should be consulted.
7. Type II leptomeningeal disease per European Association of Neuro-Oncology (EANO) -
European Society for Medical Oncology (ESMO) Clinical Practice Guidelines are
allowed.
8. Patients with confirmed ROS1 rearrangement. Prior to study enrollment, patients must
have had confirmation of ROS1 rearrangement, which should have been determined
locally by a certified laboratory using methods such as fluorescent in situ
hybridization (FISH), next generation sequencing (NGS), quantitative PCR (qPCR), or
immunohistochemistry (IHC).
9. Measurable disease according to RANO-BM criteria, with at least one measurable brain
lesion of ≥10 mm on T1-weighted, gadolinium-enhanced magnetic resonance imaging
(MRI).
10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
11. Minimum life expectancy of ≥ 6 weeks at screening.
12. No limit in number of prior chemotherapies, immunotherapy or other non-ROS1 TKI
regimens.
13. Patients must not have previously received any ROS1 TKI-based treatment.
14. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or
multigated acquisition (MUGA) scan.
15. If feasible, archival tumor biopsy sample at baseline (from primary tissue or any
metastatic site) should be provided.
16. Patient has adequate bone marrow, liver, and renal function:
I. Hematological (without platelet, red blood cell transfusion, and/or granulocyte
colony-stimulating factor support within 7 days before first study treatment dose):
White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x
109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L).
II. Hepatic: Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 3 in
patients with liver metastases or know history of Gilbert's disease); alkaline
phosphatase (ALP) ≤ 2.5 times ULN; aspartate transaminase (AST) and alanine
transaminase (ALT) ≤ 3 times ULN (≤ 5 in patients with liver metastases);
international normalized ratio (INR) < 1.5.
III. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 mL/min/1.73 m2
based on Cockcroft-Gault glomerular filtration rate estimation for patients with
creatinine levels above institutional normal.
17. Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as
determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for
Adverse Events (CTCAE) version 5.0 (v.5.0) (except for alopecia or other toxicities
not considered a safety risk for the patient at investigator's discretion).
18. Women of childbearing potential (WOCBP) who are sexually active with a
non-sterilized male partner must have a negative serum pregnancy test within 14 days
before study treatment initiation. In addition, they must agree to use one highly
effective method of birth control from the time of screening until 2 months after
the last dose of study treatments. Female patients must refrain from egg cell
donation and breastfeeding during this same period.
Note: Due to a potential loss of effectiveness of hormonal contraceptives caused by
interaction with study intervention, if WOCBP use hormonal contraceptives (including
oral hormonal contraceptives), they must use either another form of non-hormonal
highly effective contraception or a reliable barrier method.
19. Male participants who are sexually active with a WOCBP partner must be surgically
sterile or using an acceptable method of contraception from the time of screening
until 4 months after the last administration of the study drug. Male participants
must not donate or bank sperm during this same period.
20. Patient must be accessible for treatment and follow-up.
Exclusion Criteria:
Any patient meeting ANY of the following criteria will be excluded from the study:
1. Major surgery within four weeks of the start of treatment.
2. Type I leptomeningeal disease per ESMO-EANO guidelines.
3. Any of the following cardiac criteria:
I. Mean resting corrected QT interval (ECG interval measured from the onset of the
QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained from
3 ECGs, using the screening clinic ECG machine-derived QTc value.
II. Any clinically important abnormalities in rhythm, conduction or morphology of
resting ECG (e.g., complete left bundle branch block, third degree heart block,
second degree heart block, PR interval > 250 msec).
III. Any factors that increase the risk of QTc prolongation or risk of arrhythmic
events such as heart failure, hypokalemia, congenital long QT syndrome, family
history of long QT syndrome, or any concomitant medication known to prolong the QT
interval.
4. Clinically significant cardiovascular disease (either active or within 6 months
prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral
artery bypass graft, symptomatic congestive heart failure (New York Heart
Association Classification Class ≥ II), cerebrovascular accident or transient
ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic
medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.
5. Known clinically significant active infections not controlled with systemic
treatment (bacterial, fungal, viral including HIV positivity).
6. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
syndrome) or other malabsorption syndromes that would impact on drug absorption.
7. Peripheral neuropathy grade ≥ 2.
8. History of extensive, disseminated, bilateral, or presence of NCI CTCAE grade 3 or 4
interstitial fibrosis or interstitial lung disease (ILD) including a history of
pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, ILD, obliterative
bronchiolitis, and pulmonary fibrosis. Patients with a history of prior radiation
pneumonitis are not excluded.
9. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or that may interfere with the interpretation of study results
and, in the judgment of the Investigator, would make the patient inappropriate for
entry into this study or could compromise the protocol objectives in the opinion of
the Investigator.
10. Presence or history of any other primary malignancy other than NSCLC within 5 years
prior to enrollment into the study.
Note: Patients with a history of adequately treated basal or squamous cell carcinoma
of the skin or any adequately treated in situ carcinoma may be included in the
study.
11. Current use or anticipated need for drugs that are known to be strong Cytochrome
P450, family 3, subfamily A (CYP3A) inhibitors or inducers.
Note: midazolam requires diligent monitoring in situations where there is an
unprecedented necessity for co-administration. These cases should be discussed with
the study's medical monitor.
12. Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral)
corticosteroids at doses higher than 8 mg dexamethasone per day or other
immunosuppressive medications except for managing adverse events (AEs); (inhaled
steroids or intra articular steroid injections are permitted in this study).
Note: The use of stable corticosteroid therapy in patients with brain metastases should
be discussed with the Sponsor's Medical Monitor.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
November 2024
Completion date:
April 2028
Lead sponsor:
Agency:
MedSIR
Agency class:
Other
Collaborator:
Agency:
Medical University of Vienna
Agency class:
Other
Source:
MedSIR
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06315010
